NCT04561180

Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of EG-009A Compared to Dexamethasone in Patients With Moderate/Severe (Non-intubated, Non-mechanical Ventilation) COVID-19 Pneumonia

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Evergreen Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.

Conditions

• COVID-19 Pneumonia

Interventions

Type	Name	Description
DRUG	EG-009A	Administered as an Intramuscular injection
DRUG	EG-009A Placebo	Administered as an Intramuscular injection
DRUG	Standard of Care	Standard of Care Treatment for COVID-19 Infection
DRUG	Dexamethasone	The comparator, Administered as an Intravenous infusion

Timeline

• Start date: 2022-03-04
• Primary completion: 2023-05-01
• Completion: 2023-05-01
• First posted: 2020-09-23
• Last updated: 2023-07-28

Regulatory

• FDA-regulated drug study